Bilineal evolution of a U2AF1-mutated clone associated with acquisition of distinct secondary mutations.
Nathan D MontgomeryJonathan GaleottiSteven M JohnsonLeah CommanderEric T WeimerPranil K ChandraTariq NazirThomas B AlexanderJoshua F ZeidnerMatthew C FosterPublished in: Blood advances (2021)
Rare hematologic malignancies display evidence of both myeloid and lymphoid differentiation. Here, we describe such a novel bilineal event discovered in an adult woman with B-lymphoblastic leukemia (BLL). At the time of BLL diagnosis, the patient had a normal karyotype and a bulk sequencing panel identified pathogenic variants in BCOR, EZH2, RUNX1, and U2AF1, a genotype more typical of myeloid neoplasia. Additionally, the patient was noted to have 3-year history of cytopenias, and morphologic dyspoiesis was noted on post-treatment samples, raising the possibility of an antecedent hematologic disorder. To investigate the clonal architecture of her disease, we performed targeted sequencing on fractionated samples enriched for either B-lymphoblasts or circulating granulocytes. These studies revealed a truncal founder mutation in the spliceosome gene U2AF1 in both fractions, while distinct secondary mutations were present only in B-lymphoblasts (BCOR, NRAS) or myeloid cells (ASXL1, EZH2, RUNX1). These results indicate that both processes evolved from a common U2AF1-mutated precursor, which then acquired additional mutations during a process of divergent evolution and bilineal differentiation. Our findings highlight novel mechanisms in BLL leukemogenesis and expand the spectrum of observed bilineal neoplasms.
Keyphrases
- atrial fibrillation
- bone marrow
- acute myeloid leukemia
- case report
- single cell
- dendritic cells
- copy number
- induced apoptosis
- transcription factor
- wild type
- long non coding rna
- long noncoding rna
- cancer therapy
- immune response
- small cell lung cancer
- genome wide
- oxidative stress
- clear cell
- replacement therapy
- genome wide identification
- brain metastases